Globus Medical, Inc. Class A Aktie News

Globus Medical has provided preliminary fourth-quarter 2025 financial results. The company forecasts a more robust bottom line in 2026 than what analysts anticipate.

AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-report...

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.

This medical products stock breaks out of a cup-with-handle base and is in a buy zone. The company makes technology used for spine surgery.

Globus Medical's spine business is a big earnings driver, propelling its stock closer to a buy point.

Globus Medical has rebounded strongly, driven by accelerating earnings and successful integration of acquisitions like NuVasive and Nevro. The company delivered on robust Q3 results, with 7% organic growth and a significant hike in full-year adjusted earnings guidance to $3.80 per share. Despite a 35% share price surge, shares trades at a reasonable 21x earnings, supported by a strong balance s...

Shares of the medical technology company are headed for their largest same-day percentage increase on record.

The image featured for this article is © Thinkstock